CRISPR/$CRSP
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About CRISPR
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
Ticker
$CRSP
Sector
Primary listing
Employees
393
Headquarters
Zug, Switzerland
Website
CRISPR Metrics
BasicAdvanced
$5B
-
-$5.44
1.83
-
Price and volume
Market cap
$5B
Beta
1.83
52-week high
$78.48
52-week low
$30.04
Average daily volume
2.6M
Financial strength
Current ratio
16.612
Quick ratio
16.493
Long term debt to equity
11.538
Total debt to equity
12.591
Profitability
EBITDA (TTM)
-437.247
Gross margin (TTM)
-1,005.15%
Net profit margin (TTM)
-1,229.43%
Operating margin (TTM)
-1,198.98%
Effective tax rate (TTM)
-0.86%
Revenue per employee (TTM)
$100,000
Management effectiveness
Return on assets (TTM)
-13.05%
Return on equity (TTM)
-25.34%
Valuation
Price to revenue (TTM)
124.486
Price to book
2.85
Price to tangible book (TTM)
2.85
Price to free cash flow (TTM)
-13.511
Free cash flow yield (TTM)
-7.40%
Free cash flow per share (TTM)
-4.079
Growth
Revenue change (TTM)
-81.18%
Earnings per share change (TTM)
66.61%
3-year revenue growth (CAGR)
36.93%
3-year earnings per share growth (CAGR)
-12.90%
What the Analysts think about CRISPR
Analyst ratings (Buy, Hold, Sell) for CRISPR stock.
Bulls say / Bears say
US Health and Human Services Secretary Robert F. Kennedy Jr.’s commitment to fast-track rare disease drug approvals should streamline regulatory pathways for CRISPR Therapeutics’ Casgevy and upcoming gene-editing programs, potentially accelerating time-to-market (Reuters)
Positive Phase 1 data for CTX310™ demonstrated dose-dependent reductions of up to 82% in triglycerides and 81% in LDL cholesterol with a favorable safety profile, underscoring the strength of CRISPR Therapeutics’ in vivo gene-editing platform for cardiovascular indications (Nasdaq)
Eli Lilly’s impending $1.3 billion acquisition of Verve Therapeutics signals robust M&A interest in CRISPR-based therapies, suggesting that CRISPR Therapeutics could benefit from heightened investor appetite and potential strategic partnerships in the gene-editing sector (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 10 Nov 2025.
CRISPR Financial Performance
Revenues and expenses
CRISPR Earnings Performance
Company profitability
CRISPR News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for CRISPR stock?
CRISPR (CRSP) has a market cap of $5B as of November 10, 2025.
What is the P/E ratio for CRISPR stock?
The price to earnings (P/E) ratio for CRISPR (CRSP) stock is 0 as of November 10, 2025.
Does CRISPR stock pay dividends?
No, CRISPR (CRSP) stock does not pay dividends to its shareholders as of November 10, 2025.
When is the next CRISPR dividend payment date?
CRISPR (CRSP) stock does not pay dividends to its shareholders.
What is the beta indicator for CRISPR?
CRISPR (CRSP) has a beta rating of 1.83. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.